Medication class (number of trials)	Study length	Number of subjects	Ranges of A1C reductions (%)
Sulfonylurea (4)	12 weeks to 10 years	204 to 3,867	0.9 to 2.5
Alpha glucosidase inhibitor (12)	16 weeks to 2 years	40 to 495	0.4 to 1.3
Metformin (7)	11 weeks to 10.7 years	27 to 753	0.8 to 3.0
Meglitinide (4)	12 to 24 weeks	93 to 701	0.6 to 1.7
Thiazolidinedione (4)	24 to 26 weeks	402 to 959	1.1 to 1.6